NASDAQ: SSKNStrata Skin Sciences Inc Stock
$2.61-0.11 (-4.04%)
Updated Mar 26, 2025
SSKN Price
$2.61
Fair Value Price
N/A
Market Cap
$10.89M
52 Week Low
$2.51
52 Week High
$5.90
P/E
-0.98x
P/B
1.17x
P/S
0.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.68M
Earnings
-$9.38M
Gross Margin
55.5%
Operating Margin
-22.51%
Profit Margin
-28.7%
Debt to Equity
3.3
Operating Cash Flow
$991k
Beta
0.39
Next Earnings
Apr 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SSKN Overview
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SSKN's potential to beat the market
- SSKN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SSKN news, forecast changes, insider trades & much more!
SSKN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SSKN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SSKN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SSKN is good value based on its book value relative to its share price (1.17x), compared to the US Medical Devices industry average (3.95x)
P/B vs Industry Valuation
SSKN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SSKN due diligence checks available for Premium users.
Valuation
SSKN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.98x
Industry
42.28x
Market
31.65x
SSKN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
3.95x
SSKN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SSKN's financial health
Profit margin
Revenue
$8.8M
Net Income
-$2.1M
Profit Margin
-24.1%
SSKN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SSKN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$40.2M
Liabilities
$30.9M
Debt to equity
3.3
SSKN's short-term assets ($15.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSKN's long-term liabilities ($16.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSKN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SSKN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$302.0k
Investing
-$62.0k
Financing
$1.9M
SSKN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SSKN vs Medical Device Stocks
Strata Skin Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.